AstraZeneca’s investigational COVID drug meets primary goals in late-stage study

(Reuters) – AstraZeneca said on Thursday its investigational drug, sipavibart, met primary goals in preventing COVID-19 in immunocompromised patients in a late-stage trial.

(Reporting by Eva Mathews in Bengaluru; Editing by Sherry Jacob-Phillips)